Troluce Capital Advisors LLC

Position in MLYS — Mineralys Therapeutics, Inc.

CIK 1910321 DORADO, PR

Back to MLYS Full portfolio

Position in MLYS

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$46,641,755

+$28,897,805 QoQ

Shares Held

1,728,753

+163.9% QoQ

Ownership

1.96%

of shares outstanding

% of Portfolio

17.47%

of 13F equity value

Holder Rank

#14

of 226 holders

Holding Since

Mar 2026

2 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in MLYS Over Time

Shares Held

Position Value (USD)

Derivatives in MLYS

reported options exposure · as of Jun 30, 2026

CallValue

$1,349,000

CallShares

50,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Troluce Capital Advisors LLC holds $63,017,746 across 3 Biotechnology names. MLYS ranks #1 (74.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	MLYS	Mineralys Therapeutics, Inc. This page	1,728,753	$46,641,755
2	STOK	Stoke Therapeutics, Inc.	496,416	$16,242,731
3	ABVX	Abivax S.A.	1,000	$133,260

All Filings in MLYS

Export CSV

3 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,349,000	50,000	—	Call	Sole	2026-08-14
2026-06-30	$46,641,755	1,728,753	+163.9%	Shares	Sole	2026-08-14
2026-03-31	$17,743,950	655,000	—	Shares	Sole	2026-05-15
No filing history on record for this holder in this stock.